Investors

Recent Releases

December 16, 2024

Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md. , Dec. 16, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) at the U.S.

November 6, 2024

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention GAITHERSBURG, Md. , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial

November 6, 2024

Emergent BioSolutions Reports Third Quarter 2024 Financial Results

Third Quarter 2024 Total Revenues of $293.8 million , increase of 9% versus prior year Third Quarter 2024 Net Income of $114.8 million , increase of 144% versus prior year Third Quarter 2024 Adjusted EBITDA of $105.3 million , increase of 432% versus prior year Raises FY 2024 guidance GAITHERSBURG,